$5.72
(Market cap
$26,028 Mln
Recently Viewed
Clear AllMarket cap
$26,028 Mln
Revenue (TTM)
$9,811 Mln
P/E Ratio
20
P/B Ratio
1.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$1,293 Mln
ROE
0.1 %
ROCE
5.3 %
Industry P/E
--
EV/EBITDA
11
Debt to Equity
0.4
Book Value
$124.4
EPS
$8.8
Face value
--
Shares outstanding
146,758,528
CFO
$39,799.12 Mln
EBITDA
$51,067.67 Mln
Net Profit
$32,807.58 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biogen (BIIB)
| 8.9 | 5.6 | 11.0 | 64.5 | -13.3 | -6.6 | -3.7 |
|
BSE Sensex
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P 100
| 1.3 | 10.1 | 3.5 | 37.7 | 22.9 | 13.2 | 14.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Biogen (BIIB)
| 15.1 | -40.7 | -6.6 | 15.4 | -2.0 | -17.5 | -1.4 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Biogen (BIIB)
|
191.7 | 26,027.6 | 9,810.6 | 1,293.4 | 22.1 | 7.4 | 20 | 1.4 |
| 203.9 | 369,653.7 | 61,160.0 | 4,226.0 | 15.4 | 15367.3 | 88.6 | 50.5 | |
| 347.0 | 191,530.7 | 36,741.0 | 7,711.0 | 36.8 | 106.1 | 24.6 | 21.8 | |
| 59.2 | 118,584.0 | 48,194.0 | 7,053.0 | 22.2 | 40.5 | 16.8 | 6.4 | |
| 919.9 | 840,843.3 | 65,179.0 | 20,638.3 | 40.5 | 101.3 | 41 | 31.6 | |
| 133.6 | 170,839.3 | 29,443.0 | 8,510.0 | 28.8 | 40.6 | 20.3 | 7.6 | |
| 226.2 | 565,217.7 | 96,362.0 | 21,040.0 | 20.2 | 53.1 | 21.3 | 7.0 | |
| 112.7 | 300,197.8 | 65,011.0 | 18,254.0 | 33.9 | 36.9 | 16.7 | 5.7 | |
| 147.6 | 297,354.0 | 54,811.3 | 14,055.6 | 31.2 | 31.2 | 21.5 | 6.4 | |
| 26.9 | 154,837.1 | 62,579.0 | 7,770.0 | 16.3 | 8.9 | 20 | 1.8 |
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for... spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Read more
President, CEO & Director
Mr. Christopher A. Viehbacher
President, CEO & Director
Mr. Christopher A. Viehbacher
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Biogen Inc (BIIB) is $191.67 (NASDAQ) as of 22-Apr-2026 10:33 EDT. Biogen Inc (BIIB) has given a return of -13.29% in the last 3 years.
The P/E ratio of Biogen Inc (BIIB) is 20.04 times as on 17-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
19.96
|
1.41
|
|
2024
|
13.69
|
1.34
|
|
2023
|
32.47
|
2.55
|
|
2022
|
13.20
|
3.00
|
|
2021
|
22.74
|
3.25
|
The 52-week high and low of Biogen Inc (BIIB) are Rs 201.00 and Rs 115.28 as of 22-Apr-2026.
Biogen Inc (BIIB) has a market capitalisation of $ 26,028 Mln as on 17-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Biogen Inc (BIIB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.